Abstract
To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1861-1870 |
| Number of pages | 10 |
| Journal | Leukemia and Lymphoma |
| Volume | 59 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 3 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- Clinical results
- lymphoma and Hodgkin disease
- marrow and stem cell transplantation
- neoplasia
- prognostication
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation : the Memorial Sloan Kettering Cancer Center experience. / Giulino-Roth, Lisa; O’Donohue, Tara; Chen, Zhengming; Trippett, Tanya M.; Klein, Elizabeth; Kernan, Nancy A.; Kobos, Rachel; Prockop, Susan E.; Scaradavou, Andromachi; Shukla, Neerav; Steinherz, Peter G.; Moskowitz, Alison J.; Moskowitz, Craig; Boulad, Farid.
In: Leukemia and Lymphoma, Vol. 59, No. 8, 03.08.2018, p. 1861-1870.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation
T2 - the Memorial Sloan Kettering Cancer Center experience
AU - Giulino-Roth, Lisa
AU - O’Donohue, Tara
AU - Chen, Zhengming
AU - Trippett, Tanya M.
AU - Klein, Elizabeth
AU - Kernan, Nancy A.
AU - Kobos, Rachel
AU - Prockop, Susan E.
AU - Scaradavou, Andromachi
AU - Shukla, Neerav
AU - Steinherz, Peter G.
AU - Moskowitz, Alison J.
AU - Moskowitz, Craig
AU - Boulad, Farid
PY - 2018/8/3
Y1 - 2018/8/3
N2 - To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.
AB - To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p =.0015), 0.18 (p =.0039), and 0.17 (p =.0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p =.0352) and a trend toward improved EFS (HR 0.38, p =.0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.
KW - Clinical results
KW - lymphoma and Hodgkin disease
KW - marrow and stem cell transplantation
KW - neoplasia
KW - prognostication
UR - http://www.scopus.com/inward/record.url?scp=85035310453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035310453&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1403601
DO - 10.1080/10428194.2017.1403601
M3 - Article
C2 - 29183202
AN - SCOPUS:85035310453
VL - 59
SP - 1861
EP - 1870
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 8
ER -